Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 1:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–399 of 399 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Testosterone Clear all
Completed Phase 2 Interventional Results available

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer

NCT00924469
View directory record Official record
Conditions
Prostate Cancer
Interventions
Abiraterone, Leuprolide, Prednisone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
4
States / cities
Boston, Massachusetts • Houston, Texas • Seattle, Washington + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2013 · Synced Nov 13, 2026, 1:59 AM EST
Completed Phase 4 Interventional Results available

Testosterone Replacement in Men With Diabetes and Obesity

NCT01127659
View directory record Official record
Conditions
Hypogonadism
Interventions
testosterone, placebo
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
30 Years to 65 Years · Male only
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Williamsville, New York
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Nov 13, 2026, 1:59 AM EST
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Testosterone and Alendronate in Hypogonadal Men

NCT01460654
View directory record Official record
Conditions
Hypogonadism, Osteopenia, Osteoporosis
Interventions
Testosterone, Alendronate, Placebo Alendronate, Placebo Testosterone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
60 Years to 85 Years · Male only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Nov 13, 2026, 1:59 AM EST
Terminated Phase 2 Interventional Results available

Safety and Efficacy of BGS649 in Obese, Hypogonadotropic Hypogonadal Men

NCT01200862
View directory record Official record
Conditions
Obese Hypogonadotropic Hypogonadism
Interventions
Investigational new drug company code: BGS649, Placebo
Drug
Lead sponsor
Mereo BioPharma
Industry
Eligibility
30 Years to 65 Years · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Tucson, Arizona • San Diego, California • Miramar, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Nov 13, 2026, 1:59 AM EST
Active, not recruiting Phase 2 Interventional

Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers

NCT05669664
View directory record Official record
Conditions
Locally Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Unresectable Salivary Gland Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Darolutamide, Leuprolide Acetate, Magnetic Resonance Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
27
States / cities
Irvine, California • Los Angeles, California • Orange, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Nov 13, 2026, 1:59 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Feasibility of an Oral Intervention for Sexual Health in Transgender Men

NCT06470906
View directory record Official record
Conditions
Vaginal Dysbiosis, Vaginal Disease, Molecular-bacterial Vaginosis
Interventions
Probiotic Group, Placebo Group
Dietary Supplement
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Nov 13, 2026, 1:59 AM EST
Terminated Phase 2 Interventional Results available

Hypogonadism in Young Men With Type 2 Diabetes

NCT01155518
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism, Type 2 Diabetes
Interventions
testosterone, clomiphene, placebo
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 40 Years · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 4, 2019 · Synced Nov 13, 2026, 1:59 AM EST
Completed Phase 4 Interventional Accepts healthy volunteers

The Role of 5-alpha Reductase in Mediating Testosterone Actions

NCT00493987
View directory record Official record
Conditions
Healthy
Interventions
Testosterone Enanthate, Dutasteride
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 50 Years · Male only
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 13, 2010 · Synced Nov 13, 2026, 1:59 AM EST
Completed Phase 1Phase 2 Interventional Results available

Testosterone Replacement for Male Opioid Agonist Maintained Patients

NCT01873989
View directory record Official record
Conditions
Chronic Pain, Opioid Addiction, Symptomatic Hypogonadism
Interventions
Testosterone replacement, Waitlist control
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 12, 2017 · Synced Nov 13, 2026, 1:59 AM EST
Terminated Phase 2 Interventional Results available

Effects of TAK-448 in Middle-aged and Older Men With Low Testosterone

NCT02381288
View directory record Official record
Conditions
Low Testosterone
Interventions
TAK-448, TAK-448 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
60 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Nov 13, 2026, 1:59 AM EST
Completed Phase 2 Interventional Results available

Pilot Pharmacokinetic Study of Oral Testosterone Ester Formulations in Hypogonadal Men

NCT02697188
View directory record Official record
Conditions
Hypogonadism
Interventions
Testosterone undecanoate, Testosterone enanthate
Drug
Lead sponsor
Clarus Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Los Angeles, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Nov 13, 2026, 1:59 AM EST
Recruiting Phase 2 Interventional

Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism

NCT04798469
View directory record Official record
Conditions
Opioid Use, Pain, Hypogonadism, Male
Interventions
Testosterone Undecanoate 250 MG/ML, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Nov 13, 2026, 1:59 AM EST
Completed Phase 4 Interventional

Physiologic Effects of PRMS & Testosterone in the Debilitated Elderly

NCT00018356
View directory record Official record
Conditions
Muscle Weakness, Muscular Atrophy
Interventions
exercise, testosterone
Procedure · Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
65 Years and older · Male only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
No. Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2011 · Synced Nov 13, 2026, 1:59 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study of Subcutaneous Testosterone Enanthate

NCT02233751
View directory record Official record
Conditions
Hypogonadism
Interventions
Testosterone enanthate auto-injector
Combination Product
Lead sponsor
Antares Pharma Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 19, 2019 · Synced Nov 13, 2026, 1:59 AM EST
Terminated Phase 3 Interventional

Open-Label Study of ARD-0403 in Testosterone Deficient Men

NCT00562731
View directory record Official record
Conditions
Hypogonadism
Interventions
ARD-0403
Drug
Lead sponsor
Ardana Bioscience Ltd
Industry
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
12
States / cities
Huntsville, Alabama • Stanford, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2008 · Synced Nov 13, 2026, 1:59 AM EST